专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100143470A1 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING THIAZIDES AND ANGIOTENSIN-II-RECEPTOR BLOCKERS 审中-公开
标题翻译：含有THIAZIDES和ANGIOTENSIN-II-受体阻断剂的受控释放的药物组合物
公开(公告)号：US20100143470A1
公开(公告)日：2010-06-10
申请号：US12447159
申请日：2007-10-30
申请人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Jin Wook Kim , Jae Woon Son
发明人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Jin Wook Kim , Jae Woon Son
IPC分类号： A61K31/5415 , A61K47/30 , A61K47/38 , A61K47/32 , A61K9/28 , A61P9/00 , A61P13/12
CPC分类号： A61K31/00 , A61K9/2086 , A61K9/209 , A61K31/549 , A61K45/06 , A61K2300/00
摘要： Disclosed herein is a pharmaceutical composition, containing a thiazide compound and an angiotensin-II-receptor blocker, and a technology for formulating the same. More particularly, disclosed is a pharmaceutical combination formulation of thiazide compound and angiotensin-II-receptor blocker, which maximizes the pharmacological and clinical antihypertensive effects and complication preventive effects of the drugs and reduces the side effects of the drugs, compared to when single-component formulations of the drugs are administered simultaneously.
摘要翻译：本文公开了含有噻嗪类化合物和血管紧张素-II-受体阻断剂的药物组合物及其制备方法。更具体地，公开了噻嗪类化合物和血管紧张素-II-受体阻断剂的药物组合制剂，其最大化药物的药理学和临床抗高血压作用和并发症预防作用，并降低药物的副作用，与单组分药物的配方同时给药。

2. 发明申请

US20110111022A1 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：US20110111022A1
公开(公告)日：2011-05-12
申请号：US12937313
申请日：2009-04-08
申请人： Sung Wuk Kim , Sung Soo Jun , Ja Seong Koo , Jin Wook Kim , Jae Woon Son , Young Gwan Jo
发明人： Sung Wuk Kim , Sung Soo Jun , Ja Seong Koo , Jin Wook Kim , Jae Woon Son , Young Gwan Jo
IPC分类号： A61K9/52 , A61K31/41 , A61K31/4184 , A61K31/4178 , A61K9/00 , A61K9/22 , A61P9/10 , A61P9/00 , A61P9/12 , A61P3/00
CPC分类号： A61K31/41 , A61K9/0004 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/2081 , A61K9/209 , A61K9/2866 , A61K9/4808 , A61K9/5015 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K9/5078 , A61K9/5084 , A61K31/165 , A61K31/4178 , A61K31/4196 , A61K45/06 , A61K2300/00
摘要： The present invention provides a pharmaceutical formulation comprising a compartment containing a rennin inhibitor as a pharmacologically active ingredient, and a compartment having an angiotensin-II-receptor blocker as a pharmacologically active ingredient. One of the compartments is an immediate-release compartment and the other one is an extended-release compartment. Since the disclosed formulation delivers the rennin inhibitor and angiotensin-II-receptor blocker at a specific delivery rate at a different time. It has an advantage in reducing the concern about side effects, improving drug effects, and simplifying the instructions for use of the drug. In addition, the formulation can pharmacologically, clinically, scientifically, and economically achieve more useful effects than the complex prescription case of taking the ingredients separately or each at once, in preventing and treating metabolic syndrome, cardiovascular disease and renal disease.
摘要翻译：本发明提供了包含含有作为药理活性成分的肾素抑制剂的隔室的药物制剂和具有作为药理活性成分的血管紧张素-II受体阻断剂的隔室。其中一个隔间是立即释放隔间，另一个是延长隔间。由于所公开的制剂在不同时间以特定的递送速率递送肾素抑制剂和血管紧张素-II-受体阻断剂。它有利于减少对副作用的关注，改善药物作用，并简化药物使用说明书。另外，与预防和治疗代谢综合征，心血管疾病和肾脏疾病有关的成分单独或每次立即使用的复杂处方情况下，该制剂在药理学，临床上，科学上和经济上都能获得更多的有用效果。

3. 发明授权

US08642083B2 Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors 有权
标题翻译：包含血管紧张素-II受体阻断剂和HMG-CoA还原酶抑制剂的控制释放复合物组合物
公开(公告)号：US08642083B2
公开(公告)日：2014-02-04
申请号：US12513054
申请日：2007-10-30
申请人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Jae Woon Son
发明人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Jae Woon Son
IPC分类号： A61K9/42 , A61K9/40 , A61K9/36 , A61K9/28 , A61K9/20
CPC分类号： A61K31/00 , A61K9/2077 , A61K9/209
摘要： Disclosed herein is a lag time delayed-release combination pharmaceutical composition comprising of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor, as well as a preparation method thereof. The composition is designed based on chronotherapy in which active ingredients are administered to have different onset times, such that the release of each active ingredient of the composition in body can be lag time delayed to a specific rate. Also, the composition is very effective for the treatment of hypertension and the prevention of complications in patients having metabolic syndromes which show diabetes, obesity, hyperlipidemia, coronary artery diseases and the like. More specifically, the composition is a drug delivery system designed such that the release of each drug is controlled to a specific rate, and it can show the most ideal effect, when it is absorbed in body.
摘要翻译：本文公开了包含血管紧张素-II-受体阻断剂和HMG-CoA还原酶抑制剂的滞后时间延迟释放组合药物组合物及其制备方法。该组合物是基于治疗时间来设计的，其中施用活性成分具有不同的起始时间，使得组合物的每种活性成分在体内的释放可延迟到特定的速率。此外，该组合物对于治疗高血压和预防具有显示糖尿病，肥胖症，高脂血症，冠状动脉疾病等的代谢综合征的患者的并发症非常有效。更具体地，组合物是药物递送系统，其被设计成使得每种药物的释放被控制到特定的速率，并且当其被吸收在体内时它可以显示出最理想的效果。

4. 发明申请

US20110212175A1 COMBINATION PREPARATION COMPRISING ANGIOTENSIN-II-RECEPTOR BLOCKER AND HMG-COA REDUCTASE INHIBITOR 审中-公开
标题翻译：包含ANGIOTENSIN-II-受体阻断剂和HMG-COA还原酶抑制剂的组合制剂
公开(公告)号：US20110212175A1
公开(公告)日：2011-09-01
申请号：US13105739
申请日：2011-05-11
申请人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Jae Woon Son
发明人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Jae Woon Son
IPC分类号： A61K31/41 , A61K31/4178 , A61K9/24 , A61P9/12 , A61P11/00 , A61P9/00 , A61P13/12 , A61P3/00
CPC分类号： A61K9/2866 , A61K9/1652 , A61K9/2081 , A61K9/2086 , A61K9/209 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K31/41 , A61K31/4178 , A61K45/06 , A61K2300/00
摘要： Disclosed herein is a combination therapy and a combination preparation of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor characterized in that the angiotensin-II-receptor blocker is absorbed substantially later than the HMG-CoA reductase inhibitor. As the angiotensin-II-receptor blocker and the HMG-CoA reductase inhibitor are released at different times, the present combination therapy prevents competitive inhibition between the two drugs and side effects, as well as simultaneously provides synergistic effects for each active ingredient and convenience of taking the drugs.
摘要翻译：本文公开了血管紧张素-II-受体阻断剂和HMG-CoA还原酶抑制剂的组合疗法和组合制剂，其特征在于血管紧张素-II-受体阻断剂被大大晚于HMG-CoA还原酶抑制剂吸收。由于血管紧张素II受体阻断剂和HMG-CoA还原酶抑制剂在不同时间被释放，所以本发明的联合治疗可以防止两种药物之间的竞争性抑制和副作用，并且同时为每种活性成分提供协同效应和方便服用药物

5. 发明申请

US20110117194A1 PHARMACEUTICAL FORMULATION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKER 审中-公开
标题翻译：含有血管紧张素II受体阻断剂的药物制剂
公开(公告)号：US20110117194A1
公开(公告)日：2011-05-19
申请号：US12990400
申请日：2009-04-28
申请人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Ah Ram Lee , Jae Woon Son , Jeong Taek Kim
发明人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Ah Ram Lee , Jae Woon Son , Jeong Taek Kim
IPC分类号： A61K9/28 , A61K31/015 , A61K31/525 , A61K31/375 , A61K31/455 , A61K31/045 , A61K31/355 , A61K31/198 , A61K38/06 , A61K35/66 , A61K31/385 , A61K36/16 , A61K33/04 , A61K31/4178 , A61K31/41 , A61K31/4184 , A61K47/32 , A61K47/38 , A61K47/42 , A61K47/12 , A61K47/14 , A61K9/20 , A61K9/00 , A61P31/12
CPC分类号： A61K31/00 , A61K9/2081 , A61K9/2866 , A61K31/41 , A61K31/4178
摘要： The present invention provides a pharmaceutical formulation containing an angiotensin-II receptor blocker and a release-control material as a pharmacologically active ingredient and a pharmaceutical formulation comprising an immediate-release compartment and an extended-release compartment. The immediate-release compartment contains an agent as a pharmacologically active ingredient for preventing and inhibiting hepatitis and the extended-release compartment has an angiotensin-II receptor blocker as a pharmacologically active ingredient. The formulation of the present invention maximizes the effectiveness on pharmacologically and clinically lowering blood pressure and preventing complications when taking the formulation, helps to avoid interaction with a drug which is metabolized by the same enzyme in the liver, and prevents and inhibits the incidence of drug-induced hepatitis which is caused by drug administration for a long time.
摘要翻译：本发明提供含有血管紧张素-II受体阻断剂和作为药理活性成分的释放控制材料的药物制剂以及包含立即释放室和延长释放室的药物制剂。立即释放隔室含有作为预防和抑制肝炎的药理学活性成分的药剂，延长释放室具有作为药理活性成分的血管紧张素-II受体阻断剂。本发明的制剂使药物和临床上降低血压的效果最大化并且在服用制剂时预防并发症，有助于避免与由肝脏中的相同酶代谢的药物相互作用，并且预防和抑制药物的发生引起的药物长期引起的肝炎。

6. 发明授权

US08394845B2 Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor 有权
标题翻译：使用包含血管紧张素-II受体阻断剂和HMG-CoA还原酶抑制剂的组合制剂的方法
公开(公告)号：US08394845B2
公开(公告)日：2013-03-12
申请号：US13105791
申请日：2011-05-11
申请人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Jae Woon Son
发明人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Jae Woon Son
IPC分类号： A01N43/64
CPC分类号： A61K31/4178 , A61K9/1623 , A61K9/2081 , A61K9/209 , A61K9/284 , A61K9/286 , A61K9/2866 , A61K9/2886 , A61K9/4808 , A61K9/5026 , A61K9/5042 , A61K9/5084 , A61K31/4184 , A61K2300/00
摘要： Disclosed herein is a combination therapy and a combination preparation of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor characterized in that the angiotensin-II-receptor blocker is absorbed substantially later than the HMG-CoA reductase inhibitor. As the angiotensin-II-receptor blocker and the HMG-CoA reductase inhibitor are released at different times, the present combination therapy prevents competitive inhibition between the two drugs and side effects, as well as simultaneously provides synergistic effects for each active ingredient and convenience of taking the drugs.
摘要翻译：本文公开了血管紧张素-II-受体阻断剂和HMG-CoA还原酶抑制剂的组合疗法和组合制剂，其特征在于血管紧张素-II-受体阻断剂被大大晚于HMG-CoA还原酶抑制剂吸收。由于血管紧张素II受体阻断剂和HMG-CoA还原酶抑制剂在不同时间被释放，所以本发明的联合治疗可以防止两种药物之间的竞争性抑制和副作用，并且同时为每种活性成分提供协同效应和方便服用药物

7. 发明申请

US20100074951A1 CONTROLLED RELEASE COMPLEX COMPOSITION COMPRISING ANGIOTENSIN-II-RECEPTOR BLOCKERS AND HMG-COA REDUCTASE INHIBITORS 有权
标题翻译：包含血管紧张素II受体阻断剂和HMG-COA还原酶抑制剂的受控释放复合组合物
公开(公告)号：US20100074951A1
公开(公告)日：2010-03-25
申请号：US12513054
申请日：2007-10-30
申请人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Jae Woon Son
发明人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Jae Woon Son
IPC分类号： A61K9/20 , A61K9/28 , A61K9/42 , A61K9/40 , A61K9/36 , A61K31/505 , A61K31/47 , A61K31/4178 , A61K31/4184 , A61K31/404 , A61K31/40 , A61K31/366 , A61K9/24 , A61P3/10 , A61K31/41 , A61P9/00 , A61P11/00 , A61P9/12 , A61P3/00
CPC分类号： A61K31/00 , A61K9/2077 , A61K9/209
摘要： Disclosed herein is a lag time delayed-release combination pharmaceutical composition comprising of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor, as well as a preparation method thereof. The composition is designed based on chronotherapy in which active ingredients are administered to have different onset times, such that the release of each active ingredient of the composition in body can be lag time delayed to a specific rate. Also, the composition is very effective for the treatment of hypertension and the prevention of complications in patients having metabolic syndromes which show diabetes, obesity, hyperlipidemia, coronary artery diseases and the like. More specifically, the composition is a drug delivery system designed such that the release of each drug is controlled to a specific rate, and it can show the most ideal effect, when it is absorbed in body.
摘要翻译：本文公开了包含血管紧张素-II-受体阻断剂和HMG-CoA还原酶抑制剂的滞后时间延迟释放组合药物组合物及其制备方法。该组合物是基于治疗时间来设计的，其中施用活性成分具有不同的起始时间，使得组合物的每种活性成分在体内的释放可延迟到特定的速率。此外，该组合物对于治疗高血压和预防具有显示糖尿病，肥胖症，高脂血症，冠状动脉疾病等的代谢综合征的患者的并发症非常有效。更具体地，组合物是药物递送系统，其被设计成使得每种药物的释放被控制到特定的速率，并且当其被吸收在体内时它可以显示出最理想的效果。

8. 发明申请

US20120015032A1 COMBINATION PREPARATION COMPRISING INHIBITOR OF HMG-COA REDUCTASE AND ASPIRIN AND METHOD FOR MANUFACTURING THE SAME 审中-公开
标题翻译：包含HMG-COA还原酶和阿司匹林的抑制剂的组合制剂及其制备方法
公开(公告)号：US20120015032A1
公开(公告)日：2012-01-19
申请号：US12672630
申请日：2008-08-08
申请人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Sang Ouk Sun
发明人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Sang Ouk Sun
IPC分类号： A61K9/28 , A61P9/00 , A61P9/10 , A61K31/60
CPC分类号： A61K31/35 , A61K31/616 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a chronotherapeutically combined pharmaceutical formulation for preventing and treating cardiovascular diseases, which is based on the principle of administering a plurality of drugs at certain time intervals (chronotherapy). Specifically, the combined pharmaceutical formulation comprises a HMG-CoA reductase inhibitor, such as simvastatin, and aspirin. Because the combined pharmaceutical formulation was developed based on the principle of administering drugs at certain time intervals, so-called chronotherapy, it shows an excellent effect of preventing or treating cardiovascular disease compared to those of the individual administration and simultaneous administration of the single preparations. Also, it is a once-daily dosage form which increases the medication compliance of patients. Particularly, even though the content of aspirin in the combined pharmaceutical formulation is reduced, the platelet aggregation inhibitory effect of aspirin in the combined pharmaceutical formulation is equal to that of the amount of aspirin used in the prior art, while the aspirin in the combined pharmaceutical formulation shows a antihypertensive effect. In addition, the chronotherapeutically combined pharmaceutical formulation allows the two drugs, which interact with each other, to be stored for a long period of time, and the combined pharmaceutical formulation ensures the human body-safety and efficacy of the two drugs.
摘要翻译：本发明涉及一种用于预防和治疗心血管疾病的时间疗法组合药物制剂，其基于以特定时间间隔施用多种药物的原则（即时间疗法）。具体地，组合的药物制剂包含HMG-CoA还原酶抑制剂，例如辛伐他汀和阿司匹林。因为组合的药物制剂是基于以特定时间间隔给药药物的原理而开发的，即所谓的时间疗法，与单独给药和单次制剂同时给药相比，它显示了预防或治疗心血管疾病的优异效果。此外，它是一种每日一次的剂型，其增加患者的药物依从性。特别是，尽管组合药物制剂中阿司匹林的含量降低，但组合药物制剂中阿司匹林的血小板聚集抑制作用等于现有技术中所用阿司匹林的量，而组合药物中阿司匹林制剂显示抗高血压作用。另外，按时间顺序组合的药物制剂允许两种彼此相互作用的药物长时间储存，并且组合的药物制剂确保了两种药物的人体安全性和功效。

9. 发明授权

US08076377B2 N,N-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same 有权
标题翻译： N，N-二甲基亚氨基二酰亚胺二酰胺二羧酸酯，其制备方法和包含其的药物组合物
公开(公告)号：US08076377B2
公开(公告)日：2011-12-13
申请号：US12733711
申请日：2008-09-19
申请人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Young Woong Kim , Byoung Ha Kim , Duck Kim
发明人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Young Woong Kim , Byoung Ha Kim , Duck Kim
IPC分类号： A01N37/52 , A01N37/10 , A61K31/155 , A61K31/235
CPC分类号： C07C279/26 , C07C55/08 , C07C55/12 , C07C55/14 , C07C59/245
摘要： Disclosed herein are a novel dicarboxylic acid salt of N,N-dimethylimidodicarbonimidic diamide, a preparation method thereof and a pharmaceutical composition comprising the same. More specifically, disclosed herein are a novel dicarboxylic acid salt of N,N-dimethylimidodicarbonimidic diamide, a crystalline acid addition salt prepared by allowing N,N-dimethylimidodicarbonimidic diamide to react with a specific dicarboxylic acid, which has improved physical and chemical properties including solubility, stability, non-hygroscopicity and anti-adhesive properties, and low toxicity, and thus is very effective in the prevention and treatment of not only diabetes and its complications in patients with so-called metabolic syndromes, in which diabetes, obesity, hyperlipidemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndromes, etc. appear in combination, but also p53 gene-deficient cancers, muscular pain, muscle cytotoxicity and rhabdomyolysis, as well as a preparation method thereof and a pharmaceutical composition comprising the same.
摘要翻译：本文公开了N，N-二甲基亚氨基二亚甲基二酰胺的新型二羧酸盐及其制备方法和包含其的药物组合物。更具体地，本文公开了N，N-二甲基亚氨基二甲酰亚胺二酰胺的新型二羧酸盐，通过使N，N-二甲基亚氨基二碳二亚胺二酰胺与特定二羧酸反应制备的结晶酸加成盐，其具有改善的物理和化学性质，包括溶解度稳定性，非吸湿性和抗粘连性，低毒性，因此在预防和治疗不仅糖尿病及其所谓的代谢综合征患者的并发症方面非常有效，其中糖尿病，肥胖，高脂血症，脂肪肝，冠状动脉疾病，骨质疏松症，多囊卵巢综合征等组合，还包括p53基因缺陷型癌症，肌肉酸痛，肌肉细胞毒性和横纹肌溶解症，以及其制备方法和包含其的药物组合物。

10. 发明授权

US08058312B2 N, N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same 有权
标题翻译： N，N-二甲基亚氨基二甲酰亚胺二酰胺乙酸盐，其制备方法和包含其的药物组合物
公开(公告)号：US08058312B2
公开(公告)日：2011-11-15
申请号：US12524695
申请日：2008-01-29
申请人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Young Woong Kim
发明人： Sung Wuk Kim , Sung Soo Jun , Young Gwan Jo , Ja Seong Koo , Young Woong Kim
IPC分类号： A01N37/52 , A61K31/155 , C07C277/00 , C07C279/00
CPC分类号： A61K31/155 , C07C279/26
摘要： The present invention relates to N,N-dimethyl imidodicarbonimidic diamide acetate, a method of preparing the same and a pharmaceutical composition comprising the same, and more particularly, to N,N-dimethyl imidodicarbonimidic diamide acetate which is a crystalline acid addition salt prepared by reacting N,N-dimethyl imidodicarbonimidic diamide with acetic acid, and which is very effective as a therapeutic agent for treating metabolic syndromes that glycosuria and diabetes mellitus, obesity, hyperlipidemia, fatty liver, coronary heart disease, osteoporosis, polycystic ovarian syndrome, a cancer depleted of gene P53, etc. are complexly occurred; treating diabetes mellitus and preventing its complication; and treating a cancer and preventing myalgia, muscle cell cytotoxicity and rhabdomyolysis, etc. since the acid addition salt is excellent in physicochemical properties such as solubility, stability, non-hygroscopicity, anti-adhering property, etc., and low toxicity, a method of preparing the same and a pharmaceutical composition comprising the same.
摘要翻译：本发明涉及N，N-二甲基亚氨基二甲酰亚胺二酰胺乙酸盐，其制备方法和包含其的药物组合物，更具体地涉及作为结晶酸加成盐的N，N-二甲基亚氨基二甲酰亚胺二酰胺乙酸盐，其是由使N，N-二甲基亚氨基二亚甲基二酰胺与乙酸反应，作为治疗代谢综合征的糖尿病，糖尿病，肥胖症，高脂血症，脂肪肝，冠心病，骨质疏松症，多囊卵巢综合症，癌症，贫血基因P53等复杂发生; 治疗糖尿病并预防其并发症; 并且由于酸加成盐在溶解性，稳定性，非吸湿性，抗附着性等等的物理化学性质和低毒性方面都是优异的，因此治疗癌症并防止肌肉痛，肌肉细胞毒性和横纹肌溶解等。的制备方法和包含其的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式